OpenLB
Open Library of Bioscience
Advanced Search
AIDS (London, England)
04 01, 2020;34 (5): 651-658.

Sexually transmitted infections among African women: an opportunity for combination sexually transmitted infection/HIV prevention.

Jenell Stewart, Elizabeth Bukusi, Connie Celum, Sinead Delany-Moretlwe, Jared M Baeten
Author Information
  1. Jenell Stewart: Department of Medicine.
  2. Elizabeth Bukusi: Department of Global Health.
  3. Connie Celum: Department of Medicine.
  4. Sinead Delany-Moretlwe: Wits Reproductive Health and HIV Institute, University of Witwatersrand, Johannesburg, USA.
  5. Jared M Baeten: Department of Medicine.
PMID: 32167988 DOI: 10.1097/QAD.0000000000002472

Abstract

No abstract text available.

References

  1. Newman L, Rowley J, Vander Hoorn S, Wijesooriya NS, Unemo M, Low N, et al. Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting. PLoS One 2015; 10:e0143304.
  2. WHO. Global health sector strategy on sexually transmitted infections 2016-2021 towards ending STIs. Geneva: WHO Bulletin; 2016.
  3. WHO. Report on global sexually transmitted infection surveillance 2015. Geneva: Health Organization; 2016.
  4. MacLachlan E, Baganizi E, Bougoudoga F, Castle S, Mint-Youbba Z, Gorbach P, et al. The feasibility of integrated STI prevalence and behaviour surveys in developing countries. Sex Transm Dis 2002; 78:187–189.
  5. Steen R, Elvira Wi T, Kamali A, Ndowa F. Control of sexually transmitted infections and prevention of HIV transmission: mending a fractured paradigm. Bull World Health Organ 2009; 87:858–865.
  6. CDC. Sexually transmitted infections in developing countries: current concepts and strategies on Improving STI prevention, treatment, and control. Atlanta, GA: Center for Disease Control; 2008.
  7. Oliver VO, Otieno G, Gvetadze R, Desai MA, Makanga M, Akelo V, et al. High prevalence of sexually transmitted infections among women screened for a contraceptive intravaginal ring study, Kisumu, Kenya, 2014. Int J STD AIDS 2018; 956462418782810. doi: 10.1177/0956462418782810. [DOI: 10.1177/0956462418782810]
  8. Terris-Prestholt F, Vyas S, Kumaranayake L, Mayaud P, Watts C. The costs of treating curable sexually transmitted infections in low- and middle-income countries: a systematic review. Sex Transm Dis 2006; 33: (10 Suppl): S153–S166.
  9. Cherutich P, Kaiser R, Galbraith J, Williamson J, Shiraishi RW, Ngare C, et al. KAIS Study Group. Lack of knowledge of HIV status a major barrier to HIV prevention, care and treatment efforts in Kenya: results from a nationally representative study. PLoS One 2012; 7:e36797.
  10. UNAIDS. The gap report. Geneva: UNAIDS; 2015.
  11. Kamali A, Price MA, Lakhi S, Karita E, Inambao M, Sanders EJ, et al. IAVI Africa HIV Prevention Partnership. Creating an African HIV clinical research and prevention trials network: HIV prevalence, incidence and transmission. PLoS One 2015; 10:e0116100.
  12. De Cock KM, Jaffe HW, Curran JW. The evolving epidemiology of HIV/AIDS. AIDS 2012; 26:1205–1213.
  13. Stephens AJ, Aubuchon M, Schust DJ. Antichlamydial antibodies, human fertility, and pregnancy wastage. Infect Dis Obstet Gynecol 2011; 2011:525182.
  14. Masese LN, Graham SM, Gitau R, Peshu N, Jaoko W, Ndinya-Achola JO, et al. A prospective study of vaginal trichomoniasis and HIV-1 shedding in women on antiretroviral therapy. BMC Infect Dis 2011; 11:307.
  15. Hoenderboom BM, van Benthem BHB, van Bergen J, Dukers-Muijrers N, Gotz HM, Hoebe C, et al. Relation between Chlamydia trachomatis infection and pelvic inflammatory disease, ectopic pregnancy and tubal factor infertility in a Dutch cohort of women previously tested for chlamydia in a chlamydia screening trial. Sex Transm Infect 2019; 95:300–306.
  16. Davies B, Turner KME, Frolund M, Ward H, May MT, Rasmussen S, et al. Risk of reproductive complications following chlamydia testing: a population-based retrospective cohort study in Denmark. Lancet Infect Dis 2016; 16:1057–1064.
  17. Schwartz RM, Bruno DM, Augenbraun MA, Hogben M, Joseph MA, Liddon N, et al. Perceived financial need and sexual risk behavior among urban, minority patients following sexually transmitted infection diagnosis. Sex Transm Dis 2011; 38:230–234.
  18. Goyette MS, Mutiti PM, Bukusi D, Wamuti BM, Otieno FA, Cherutich P, et al. Brief report: HIV assisted partner services among those with and without a history of intimate partner violence in Kenya. J Acquir Immune Defic Syndr 2018; 78:16–19.
  19. Schaffer EM, Agot K, Thirumurthy H. The association between intimate partner violence and women's distribution and use of HIV self-tests with male partners: evidence from a cohort study in Kenya. J Acquir Immune Defic Syndr 2017; 76:e85–e87.
  20. Zemouri C, Wi TE, Kiarie J, Seuc A, Mogasale V, Latif A, et al. The performance of the vaginal discharge syndromic management in treating vaginal and cervical infection: a systematic review and meta-analysis. PLoS One 2016; 11:e0163365.
  21. Verwijs MC, Agaba SK, Sumanyi JC, Umulisa MM, Mwambarangwe L, Musengamana V, et al. Targeted point-of-care testing compared with syndromic management of urogenital infections in women (WISH): a cross-sectional screening and diagnostic accuracy study. Lancet Infect Dis 2019; 19:658–669.
  22. Nguyen VK, Greenwald ZR, Trottier H, Cadieux M, Goyette A, Beauchemin M, et al. Incidence of sexually transmitted infections before and after preexposure prophylaxis for HIV. Aids 2018; 32:523–530.
  23. Traeger MW, Cornelisse VJ, Asselin J, Price B, Roth NJ, Willcox J, et al. PrEPX Study Team. Association of HIV preexposure prophylaxis with incidence of sexually transmitted infections among individuals at high risk of HIV infection. JAMA 2019; 321:1380–1390.
  24. Montano MA, Dombrowski JC, Dasgupta S, Golden MR, Manhart LE, Barbee LA, et al. Differences in sexually transmitted infection risk comparing preexposure prophylaxis users and propensity score matched historical controls in a clinic setting. AIDS 2019; 33:1773–1780.
  25. Cohen MS, Gay CL. Treatment to prevent transmission of HIV-1. Clin Infect Dis 2010; 50: (Suppl 3): S85–S95.
  26. Rendina HJ, Parsons JT. Factors associated with perceived accuracy of the Undetectable = Untransmittable slogan among men who have sex with men: implications for messaging scale-up and implementation. J Int AIDS Soc 2018; 21:e25055.
  27. Golden MR, Stekler J, Hughes JP, Wood RW. HIV serosorting in men who have sex with men: is it safe?. J Acquir Immune Defic Syndr 2008; 49:212–218.
  28. Holt M, Lea T, Mao L, Kolstee J, Zablotska I, Duck T, et al. Community-level changes in condom use and uptake of HIV preexposure prophylaxis by gay and bisexual men in Melbourne and Sydney, Australia: results of repeated behavioural surveillance in 2013-17. Lancet HIV 2018; 5:e448–e456.
  29. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Partners PrEP Study Team. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367:399–410.
  30. Brown AE, Mohammed H, Ogaz D, Kirwan PD, Yung M, Nash SG, et al. Fall in new HIV diagnoses among men who have sex with men (MSM) at selected London sexual health clinics since early 2015: testing or treatment or preexposure prophylaxis (PrEP)?. Euro Surveill 2017; 22:30553.
  31. Mmeje O, Wallett S, Kolenic G, Bell J. Impact of expedited partner therapy (EPT) implementation on chlamydia incidence in the USA. Sex Transm Infect 2018; 94:545–547.
  32. Golden MR, Katz DA, Dombrowski JC. Modernizing field services for human immunodeficiency virus and sexually transmitted infections in the United States. Sex Transm Dis 2017; 44:599–607.
  33. Eaton LA, Kalichman SC, Kalichman MO, Driffin DD, Baldwin R, Zohren L, et al. Randomised controlled trial of a sexual risk reduction intervention for STI prevention among men who have sex with men in the USA. Sex Transm Infect 2018; 94:40–45.
  34. CDC. Preexposure prophylaxis for the prevention of HIV infection in the United States–2017 Update: a clinical practice guideline. Atlanta, GA: CDC; 2017.
  35. Hodges-Mameletzis I, Dalal S, Msimanga-Radebe B, Rodolph M, Baggaley R. Going global: the adoption of the World Health Organization's enabling recommendation on oral preexposure prophylaxis for HIV. Sex Health 2018; 15:489–500.
  36. Raifman JR, Schwartz SR, Sosnowy CD, Montgomery MC, Almonte A, Bazzi AR, et al. Brief report: preexposure prophylaxis awareness and use among cisgender women at a sexually transmitted disease clinic. J Acquir Immune Defic Syndr 2019; 80:36–39.
  37. Sales JM, Steiner RJ, Brown JL, Swartzendruber A, Patel AS, Sheth AN. PrEP eligibility and interest among clinic- and community-recruited young black women in Atlanta, Georgia, USA. Curr HIV Res 2018; 16:250–255.
  38. Baeten JM, Palanee-Phillips T, Brown ER, Schwartz K, Soto-Torres LE, Govender V, et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med 2016; 375:2121–2132.
  39. Kiweewa FM, Brown E, Mishra A, Nair G, Palanee-Phillips T, Mgodi N, Nakabiito C, Chakhtoura N, Hillier SL, Baeten JM; MTN-020/ASPIRE Study Team. Acquisition of Sexually Transmitted Infections among Women Using a Variety of Contraceptive Options: A prospective Study among High-risk African Women. J Int AIDS Soc. 2019 Feb;22(2):e25257. doi: 10.1002/jia2.25257. Erratum in: J Int AIDS Soc. 2019 Apr;22(4):e25280. PMID: 30816632; PMCID: PMC6393855.
  40. Morton J, Bukusi E, Delany-Moretlwe S, Bekker LG, Omollo V, Travill D, et al. High prevalence of curable STIs among young women initiating PrEP in Kenya and South Africa. In: AIDS 2018: 22nd International AIDS Conference. Amsterdam, Netherlands; 2018.
  41. Travill D, Delany-Moretlwe S, Bekker LG, Bukusi E, Rousseau E, Omollo V, et al. Sexual behavior and PrEP uptake among young African women in a demonstration project about PrEP delivery. In: AIDS 2018: 22nd International AIDS Conference. Amsterdam, Netherlands; 2018.
  42. CDC. New CDC analysis shows steep and sustained increases in STDs in recent years. In: CDC Newsroom Releases; 2018.
  43. Cehovin A, Harrison OB, Lewis SB, Ward PN, Ngetsa C, Graham SM, et al. Identification of novel Neisseria gonorrhoeae lineages harboring resistance plasmids in Coastal Kenya. J Infect Dis 2018; 218:801–808.
  44. Kularatne R, Maseko V, Gumede L, Kufa T. Trends in Neisseria gonorrhoeae antimicrobial resistance over a ten-year surveillance period, Johannesburg, South Africa, 2008-2017. Antibiotics (Basel) 2018; 7:
  45. Wi T, Lahra MM, Ndowa F, Bala M, Dillon JR, Ramon-Pardo P, et al. Antimicrobial resistance in Neisseria gonorrhoeae: global surveillance and a call for international collaborative action. PLoS Med 2017; 14:e1002344.
  46. Soge OO, Salipante SJ, No D, Duffy E, Roberts MC. In vitro activity of delafloxacin against clinical Neisseria gonorrhoeae isolates and selection of gonococcal delafloxacin resistance. Antimicrob Agents Chemother 2016; 60:3106–3111.
  47. Lahra MM, Ryder N, Whiley DM. A new multidrug-resistant strain of Neisseria gonorrhoeae in Australia. N Engl J Med 2014; 371:1850–1851.
  48. Read P, Tagg KA, Jeoffreys N, Guy RJ, Gilbert GL, Donovan B. Treponema pallidum strain types and association with macrolide resistance in Sydney, Australia: new TP0548 gene types identified. J Clin Microbiol 2016; 54:2172–2174.
  49. Kanai M, Arima Y, Nishiki S, Shimuta K, Itoda I, Matsui T, et al. Molecular typing and macrolide resistance analyses of Treponema pallidum in heterosexuals and men who have sex with men in Japan, 2017. J Clin Microbiol 2019; 57: pii: e01167-18.
  50. Sweeney EL, Trembizki E, Bletchly C, Bradshaw CS, Menon A, Francis F, et al. Levels of Mycoplasma genitalium antimicrobial resistance differ by both region and gender in the state of Queensland, Australia: implications for treatment guidelines. J Clin Microbiol 2019; 57: pii: e01555-18.
  51. Maduna LD, Laumen JG, Radebe O, Kock MM, Peters RP. Failure of syndromic management due to drug-resistant Mycoplasma genitalium infection in South Africa: a case report. Int J STD AIDS 2019; 30:519–521.
  52. Sandoz KM, Rockey DD. Antibiotic resistance in Chlamydiae. Future Microbiol 2010; 5:1427–1442.
  53. Schautteet K, De Clercq E, Miry C, Van Groenweghe F, Delava P, Kalmar I, et al. Tetracycline-resistant Chlamydia suis in cases of reproductive failure on Belgian, Cypriote and Israeli pig production farms. J Med Microbiol 2013; 62 (Pt 2):331–334.
  54. Borel N, Regenscheit N, Di Francesco A, Donati M, Markov J, Masserey Y, Pospischil A. Selection for tetracycline-resistant Chlamydia suis in treated pigs. Vet Microbiol 2012; 156:143–146.
  55. Mehta SD, Maclean I, Ndinya-Achola JO, Moses S, Martin I, Ronald A, et al. Emergence of quinolone resistance and cephalosporin MIC creep in Neisseria gonorrhoeae isolates from a cohort of young men in Kisumu, Kenya, 2002 to 2009. Antimicrob Agents Chemother 2011; 55:3882–3888.
  56. Fayemiwo SA, Muller EE, Gumede L, Lewis DA. Plasmid-mediated penicillin and tetracycline resistance among Neisseria gonorrhoeae isolates in South Africa: prevalence, detection and typing using a novel molecular assay. Sex Transm Dis 2011; 38:329–333.
  57. WHO. Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae. Report on global sexually transmitted infection surveillance. Geneva: World Health Organization; 2018.
  58. Cao V, Ratsima E, Van Tri D, Bercion R, Fonkoua MC, Richard V, et al. Antimicrobial susceptibility of Neisseria gonorrhoeae strains isolated in 2004–2006 in Bangui, Central African Republic; Yaounde, Cameroon; Antananarivo, Madagascar; and Ho Chi Minh Ville and Nha Trang, Vietnam. Sex Transm Dis 2008; 35:941–945.
  59. Vandepitte J, Hughes P, Matovu G, Bukenya J, Grosskurth H, Lewis DA. High prevalence of ciprofloxacin-resistant gonorrhea among female sex workers in Kampala, Uganda (2008–2009). Sex Transm Dis 2014; 41:233–237.
  60. Taylor SN, Marrazzo J, Batteiger BE, Hook EW 3rd, Sena AC, Long J, et al. Single-dose zoliflodacin (ETX0914) for treatment of urogenital gonorrhea. N Engl J Med 2018; 379:1835–1845.
  61. Chen MY, McNulty A, Avery A, Whiley D, Tabrizi SN, Hardy D, et al. Solitaire-U Team. Solithromycin versus ceftriaxone plus azithromycin for the treatment of uncomplicated genital gonorrhoea (SOLITAIRE-U): a randomised phase 3 noninferiority trial. Lancet Infect Dis 2019; 19:833–842.
  62. Taylor SN, Morris DH, Avery AK, Workowski KA, Batteiger BE, Tiffany CA, et al. Gepotidacin for the treatment of uncomplicated urogenital gonorrhea: a phase 2, randomized, dose-ranging, single-oral dose evaluation. Clin Infect Dis 2018; 67:504–512.
  63. Schillinger JA, Kissinger P, Calvet H, Whittington WL, Ransom RL, Sternberg MR, et al. Patient-delivered partner treatment with azithromycin to prevent repeated Chlamydia trachomatis infection among women: a randomized, controlled trial. Sex Transm Dis 2003; 30:49–56.
  64. Golden MR, Whittington WL, Handsfield HH, Hughes JP, Stamm WE, Hogben M, et al. Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection. N Engl J Med 2005; 352:676–685.
  65. Kaul R, Kimani J, Nagelkerke NJ, Fonck K, Ngugi EN, Keli F, et al. Kibera HIV Study Group. Monthly antibiotic chemoprophylaxis and incidence of sexually transmitted infections and HIV-1 infection in Kenyan sex workers: a randomized controlled trial. JAMA 2004; 291:2555–2562.
  66. Bolan RK, Beymer MR, Weiss RE, Flynn RP, Leibowitz AA, Klausner JD. Doxycycline prophylaxis to reduce incident syphilis among HIV-infected men who have sex with men who continue to engage in high-risk sex: a randomized, controlled pilot study. Sex Transm Dis 2015; 42:98–103.
  67. Molina JM, Charreau I, Chidiac C, Pialoux G, Cua E, Delaugerre C, et al. Postexposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial. Lancet Infect Dis 2018; 18:308–317.
  68. Petousis-Harris H, Paynter J, Morgan J, Saxton P, McArdle B, Goodyear-Smith F, Black S. Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study. Lancet 2017; 390:1603–1610.
  69. Weiss KM, Jones JS, Anderson EJ, Gift T, Chesson H, Bernstein K, et al. Optimizing coverage vs frequency for sexually transmitted infection screening of men who have sex with men. Open Forum Infect Dis 2019; 6:ofz405.
  70. Moore MS, Golden MR, Scholes D, Kerani RP. Assessing trends in chlamydia positivity and gonorrhea incidence and their associations with the incidence of pelvic inflammatory disease and ectopic pregnancy in Washington State, 1988–2010. Sex Transm Dis 2016; 43:2–8.
  71. Wingrove I, McOwan A, Nwokolo N, Whitlock G. Diagnostics within the clinic to test for gonorrhoea and chlamydia reduces the time to treatment: a service evaluation. Sex Transm Infect 2014; 90:474.
  72. Toskin I, Blondeel K, Peeling RW, Deal C, Kiarie J. Advancing point of care diagnostics for the control and prevention of STIs: the way forward. Sex Transm Infect 2017; 93 (S4):S81–S88.
  73. Peeling RWW, Mabey D. Point-of-care tests to reduce the burden of sexually transmitted infections. Lancet Infect Dis 2019; 19:570–571.
  74. Gaydos C, Hardick J. Point of care diagnostics for sexually transmitted infections: perspectives and advances. Exp Rev Antiinfect Ther 2014; 12:657–672.
  75. Badman SG, Causer LM, Guy R, Tabrizi SN, Francis F, Donovan B, Whiley D. TTANGO investigators. A preliminary evaluation of a new GeneXpert (Gx) molecular point-of-care test for the detection of Trichomonas vaginalis. Sex Transm Infect 2016; 92:350–352.
  76. Jacobsson S, Boiko I, Golparian D, Blondeel K, Kiarie J, Toskin I, et al. WHO laboratory validation of Xpert((R)) CT/NG and Xpert((R)) TV on the GeneXpert system verifies high performances. APMIS 2018; 126:907–912.
  77. Causer LM, Guy RJ, Tabrizi SN, Whiley DM, Speers DJ, Ward J, et al. Molecular test for chlamydia and gonorrhoea used at point of care in remote primary healthcare settings: a diagnostic test evaluation. Sex Transm Infect 2018; 94:340–345.
  78. Garrett NJ, Osman F, Maharaj B, Naicker N, Gibbs A, Norman E, et al. Beyond syndromic management: opportunities for diagnosis-based treatment of sexually transmitted infections in low- and middle-income countries. PLoS One 2018; 13:e0196209.
  79. Herbst de Cortina S, Bristow CC, Joseph Davey D, Klausner JD. A systematic review of point of care testing for Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis. Infect Dis Obstet Gynecol 2016; 2016:4386127.
  80. Widdice LE, Hsieh YH, Silver B, Barnes M, Barnes P, Gaydos CA. Performance of the Atlas genetics rapid test for chlamydia trachomatis and women's attitudes toward point-of-care testing. Sex Transm Dis 2018; 45:723–727.
  81. Hosenfeld CB, Workowski KA, Berman S, Zaidi A, Dyson J, Mosure D, et al. Repeat infection with Chlamydia and gonorrhea among females: a systematic review of the literature. Sex Transm Dis 2009; 36:478–489.
  82. Kissinger P, Brown R, Reed K, Salifou J, Drake A, Farley TA, Martin DH. Effectiveness of patient delivered partner medication for preventing recurrent Chlamydia trachomatis. Sex Transm Infect 1998; 74:331–333.
  83. Gift TL, Kissinger P, Mohammed H, Leichliter JS, Hogben M, Golden MR. The cost and cost-effectiveness of expedited partner therapy compared with standard partner referral for the treatment of chlamydia or gonorrhea. Sex Transm Dis 2011; 38:1067–1073.
  84. Taleghani S, Joseph-Davey D, West SB, Klausner HJ, Wynn A, Klausner JD. Acceptability and efficacy of partner notification for curable sexually transmitted infections in sub-Saharan Africa: a systematic review. Int J STD AIDS 2019; 30:292–303.
  85. Steen R, Vuylsteke B, DeCoito T, Ralepeli S, Fehler G, Conley J, et al. Evidence of declining STD prevalence in a South African mining community following a core-group intervention. Sex Transm Dis 2000; 27:1–8.
  86. Holmes KK, Johnson DW, Kvale PA, Halverson CW, Keys TF, Martin DH. Impact of a gonorrhea control program, including selective mass treatment, in female sex workers. J Infect Dis 1996; 174: (Suppl 2): S230–S239.
  87. Grosskurth H, Mosha F, Todd J, Mwijarubi E, Klokke A, Senkoro K, et al. Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. Lancet 1995; 346:530–536.
  88. Kamali A, Quigley M, Nakiyingi J, Kinsman J, Kengeya-Kayondo J, Gopal R, et al. Syndromic management of sexually-transmitted infections and behaviour change interventions on transmission of HIV-1 in rural Uganda: a community randomised trial. Lancet 2003; 361:645–652.
  89. Gregson S, Adamson S, Papaya S, Mundondo J, Nyamukapa CA, Mason PR, et al. Impact and process evaluation of integrated community and clinic-based HIV-1 control: a cluster-randomised trial in eastern Zimbabwe. PLoS Med 2007; 4:e102.
  90. Wawer MJ, Sewankambo NK, Serwadda D, Quinn TC, Paxton LA, Kiwanuka N, et al. Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomised community trial. Rakai Project Study Group. Lancet 1999; 353:525–535.
  91. Gray RH, Wabwire-Mangen F, Kigozi G, Sewankambo NK, Serwadda D, Moulton LH, et al. Randomized trial of presumptive sexually transmitted disease therapy during pregnancy in Rakai, Uganda. Am J Obstet Gynecol 2001; 185:1209–1217.
  92. Steen R, Chersich M, Gerbase A, Neilsen G, Wendland A, Ndowa F, et al. Periodic presumptive treatment of curable sexually transmitted infections among sex workers: a systematic review. AIDS 2012; 26:437–445.
  93. WHO. Periodic presumptive treatment for sexually transmitted infections: experience from the field and recommendations for research. Geneva: World Health Organization; 2008.
  94. Golden MR, Handsfield HH. Preexposure prophylaxis to prevent bacterial sexually transmitted infections in men who have sex with men. Sex Transm Dis 2015; 42:104–106.
  95. Nadelman RB, Nowakowski J, Fish D, Falco RC, Freeman K, McKenna D, et al. Tick Bite Study Group. Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an Ixodes scapularis tick bite. N Engl J Med 2001; 345:79–84.
  96. Tan KR, Magill AJ, Parise ME, Arguin PM. Centers for Disease Control and Prevention. Doxycycline for malaria chemoprophylaxis and treatment: report from the CDC expert meeting on malaria chemoprophylaxis. Am J Trop Med Hyg 2011; 84:517–531.
  97. Chusri S, McNeil EB, Hortiwakul T, Charernmak B, Sritrairatchai S, Santimaleeworagun W, et al. Single dosage of doxycycline for prophylaxis against leptospiral infection and leptospirosis during urban flooding in southern Thailand: a nonrandomized controlled trial. J Infect Chemother 2014; 20:709–715.
  98. Identifier NCT03980223, evaluation of doxycycline postexposure prophylaxis to reduce sexually transmitted infections in PrEP users and HIV-infected men who have sex with men. In: ClinicalTrialsgov. June. 10 ed. Bethesda (MD): National Library of Medicine (US); 2019.
  99. Grant JS, Stafylis C, Celum C, Grennan T, Haire B, Kaldor J, et al. Doxycycline prophylaxis for bacterial sexually transmitted infections. Clin Infect Dis 2019; pii: ciz866. doi: 10.1093/cid/ciz866. [Epub ahead of print]. [DOI: 10.1093/cid/ciz866.]
  100. Doxycycline PEP for prevention of sexually transmitted infections among Kenyan women using HIV PrEP. In: ClinicalTrialsgov Identifier: NCT04050540. ClinicalTrials.gov; 2019.
  101. Raymond EG, Shochet T, Drake JK, Westley E. What some women want? On-demand oral contraception. Contraception 2014; 90:105–110.
  102. Chin-Quee D, L’Engle K, Otterness C. Prospects for coitally-dependent hormonal contraception: perspectives from women in urban Kenya and Nigeria. J Fam Plann Reprod Healthcare 2014; 40:170–176.
  103. Gottlieb SL, Deal CD, Giersing B, Rees H, Bolan G, Johnston C, et al. The global roadmap for advancing development of vaccines against sexually transmitted infections: update and next steps. Vaccine 2016; 34:2939–2947.
  104. Jiao H, Yang H, Zhao D, Chen J, Zhang Q, Liang J, et al. Design and immune characterization of a novel Neisseria gonorrhoeae DNA vaccine using bacterial ghosts as vector and adjuvant. Vaccine 2018; 36:4532–4539.
  105. Edwards JL, Jennings MP, Seib KL. Neisseria gonorrhoeae vaccine development: hope on the horizon?. Curr Opin Infect Dis 2018; 31:246–250.
  106. Russi RC, Bourdin E, Garcia MI, Veaute CMI. In silico prediction of T- and B-cell epitopes in PmpD: first step towards to the design of a Chlamydia trachomatis vaccine. Biomed J 2018; 41:109–117.
  107. Hafner LM, Timms P. Development of a Chlamydia trachomatis vaccine for urogenital infections: novel tools and new strategies point to bright future prospects. Expert Rev Vaccines 2018; 17:57–69.
  108. Identifier NCT03926728, safety and immunogenicity of a Chlamydia vaccine CTH522 (CHLM-02). In: ClinicalTrialsgov. April 24 ed. Bethesda (MD): National Library of Medicine (US); 2019.
  109. Beernink PT, Ispasanie E, Lewis LA, Ram S, Moe GR, Granoff DM. A meningococcal native outer membrane vesicle vaccine with attenuated endotoxin and overexpressed factor h binding protein elicits gonococcal bactericidal antibodies. J Infect Dis 2019; 219:1130–1137.
  110. Gottlieb SL, Jerse AE, Delany-Moretlwe S, Deal C, Giersing BK. Advancing vaccine development for gonorrhoea and the global sexually transmissible infection vaccine roadmap. Sex Health 2019; doi: 10.1071/SH19060. [Epub ahead of print]. [DOI: 10.1071/sh19060.]
  111. Stover J, Bollinger L, Izazola JA, Loures L, DeLay P, Ghys PD, et al. Fast Track modeling working group. What is required to end the AIDS epidemic as a public health threat by 2030? The cost and impact of the fast-track approach. PLoS One 2016; 11:e0154893.
  112. Cremin I, McKinnon L, Kimani J, Cherutich P, Gakii G, Muriuki F, et al. PrEP for key populations in combination HIV prevention in Nairobi: a mathematical modelling study. Lancet HIV 2017; 4:e214–e222.

Grants

  1. P30 AI027757/NIAID NIH HHS
  2. R01 AI145971/NIAID NIH HHS
  3. R01 MH095507/NIMH NIH HHS
  4. T32 AI007044/NIAID NIH HHS

MeSH Term

Adult
Delivery of Health Care, Integrated
Female
HIV Infections
Humans
Point-of-Care Testing
Sexually Transmitted Diseases
Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.
Article has an altmetric score of 9

Word Cloud

Created with Highcharts 10.0.0transmittedSexuallyinfectionsamongAfricanwomen:opportunitycombinationsexuallyinfection/HIVprevention

Similar Articles

Cited By